The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of hyperfractionated low-dose radiotherapy (RT) as a chemotherapy sensitizer in combination with gemcitabine (G) and erlobtinib (E) in advanced pancreatic cancer.
Andre A. Konski
Research Funding - Genentech
Joshua E. Meyer
No relevant relationships to disclose
Philip Agop Philip
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Anthony Frank Shields
No relevant relationships to disclose
Michael J. Hall
No relevant relationships to disclose
Minsig Choi
No relevant relationships to disclose
Gail Duncan
No relevant relationships to disclose
Beth Adaire
No relevant relationships to disclose
Erin McSpadden
No relevant relationships to disclose
Steven J. Cohen
Honoraria - Genentech